Loading organizations...
Lyra Capital acquires and grows businesses facing succession challenges, operating within Novastone Capital Advisors’ Entrepreneurship through Acquisition program. The firm employs a people-centric approach for business transitions, integrating post-acquisition strategies with change management. It aims to create value for employees, customers, and shareholders, actively pursuing accretive M&A opportunities within fragmented markets.
Martine Legault, P.Eng., MBA, serves as managing partner, leveraging her experience as a former CEO and business owner. Lyra Capital’s foundation stems from the insight that successful business transfers, especially those with succession, require a balanced, human-focused methodology. This belief underpins their operational framework, ensuring continuity and growth for acquired entities.
The firm partners with owners of small and medium-sized enterprises (SMEs) preparing for business transitions. Lyra Capital’s vision is to be a trusted partner in succession planning, transforming businesses into resilient ventures through strategic investment and operational improvements, enabling smooth evolution and expansion under new leadership.
Lyra Capital has 2 tracked investments across 2 companies. The latest tracked deal is $400.0M Series A in Kailera Therapeutics in October 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 7, 2024 | Kailera Therapeutics | $400.0M Series A | Gotham Makker, Michael Gladstone, Atlas Venture, Bain Capital Life Sciences, RTW Investments | — |
| Jun 30, 2021 | ArriVent Biopharma | $150.0M Series A | Hillhouse Capital Group | Lilly Asia Ventures, Octagon Capital, OrbiMed, ZOO Capital |